WO2020204242A1 - Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale - Google Patents

Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale Download PDF

Info

Publication number
WO2020204242A1
WO2020204242A1 PCT/KR2019/004204 KR2019004204W WO2020204242A1 WO 2020204242 A1 WO2020204242 A1 WO 2020204242A1 KR 2019004204 W KR2019004204 W KR 2019004204W WO 2020204242 A1 WO2020204242 A1 WO 2020204242A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
extract
composition
sambaekcho
yolk powder
Prior art date
Application number
PCT/KR2019/004204
Other languages
English (en)
Korean (ko)
Inventor
조명행
김도형
Original Assignee
(주)지웰바이오
조명행
김도형
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)지웰바이오, 조명행, 김도형 filed Critical (주)지웰바이오
Publication of WO2020204242A1 publication Critical patent/WO2020204242A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts
    • A23V2250/2044—Egg yolk

Definitions

  • the present invention is an antibacterial composition for inhibiting oral bacteria capable of preventing, improving and treating oral diseases by inhibiting bacteria and oral inflammation causing oral diseases, pharmaceutical compositions for preventing or treating oral diseases, health functional food compositions and quasi-drug compositions. About.
  • the present invention relates to an oral disintegrating film for inhibiting oral bacteria.
  • More than 400 kinds of bacteria are proliferating in human oral cavity, and the number of bacteria reaches 10 billion, and it is known that there are bacteria at the level of 10 8 ⁇ 10 9 CFU/ml in saliva.
  • the teeth are perforated with a large number of microscopic holes, so bacteria that cause tooth decay enter the perforated hole and make the tooth sick. This is caries.
  • Dental caries and periodontal disease are infectious oral diseases, which prevent caries-causing bacteria such as Streptococcus mutans and/or periodontopathogenic bacteria such as Porphyromonas gingivalis. It is known to be associated with dental plaque.
  • Anti-plaque chemicals or antibiotics such as vancomycin are used to suppress the bacteria that cause such oral infections.
  • conventionally used materials are limited in clinical use due to problems such as unpleasant bitter taste, tooth discoloration, and resistance to antibiotics.
  • formulations administered orally include various oral dissolution formulations such as tablets, chewable tablets, sublingual tablets, capsules, and liquids.
  • general tablets and capsules have disadvantages of difficulty in taking drugs, such as animals, and liquid preparations have disadvantages of poor stability and inaccurate dosage.
  • an oral disintegrating tablet was recently developed in which a solid drug was developed in an oral disintegration form.
  • oral disintegrating tablets have the disadvantage of additionally drinking water, so there is a need for a new oral disintegrating film formulation.
  • the newly developed oral disintegrating film formulation has the advantage that it can be taken without water, and since it disintegrates in the oral cavity, it can be easily taken.
  • the present inventors were discussing a method to effectively inhibit oral bacteria and inhibit inflammation.When using a mixture of egg yolk powder, Sambaekcho extract, and Eoseongcho extract, it exhibits effective antibacterial activity against oral bacteria and prevents inflammation induced by oral cells. It was confirmed that it can be effectively suppressed and the present invention was completed. In addition, it was confirmed that the convenience of taking can be improved by preparing an oral disintegrating film containing them.
  • an object of the present invention is to provide an antibacterial composition for inhibiting oral bacteria including egg yolk powder, Eoseongcho extract and Sambaekcho extract, a pharmaceutical composition for preventing or treating oral diseases, a health functional food composition, a quasi-drug composition, and an oral disintegrating film containing them. To provide.
  • the present invention provides an antibacterial composition for inhibiting oral bacteria comprising egg yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention provides a pharmaceutical composition for preventing or treating oral diseases comprising yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention provides a health functional food composition for preventing or improving oral diseases, including yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention provides a quasi-drug composition for preventing or improving oral diseases, including egg yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention provides a veterinary composition for preventing or improving oral diseases comprising egg yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention provides a composition for preparing an oral disintegrating film for preventing or improving oral diseases, including egg yolk powder, Eoseongcho extract, Sambaekcho extract, and film forming agent.
  • the present invention provides an oral disintegrating film for preventing or improving oral diseases comprising egg yolk powder, Eoseongcho extract, Sambaekcho extract, and film forming agent.
  • the egg yolk powder, Eoseongcho extract and Sambaekcho extract of the present invention inhibit inflammation induced by infection with periodontal disease-causing bacteria, and effectively inhibit Porphyromonas gingivalins or Porphyromonas canginibalis, which are representative oral bacteria, at low concentrations. Since it can, it can be usefully used in the prevention or treatment of various oral diseases.
  • the yolk powder, Eoseongcho extract, and Sambaekcho extract of the present invention are prepared as an oral disintegrating film to improve the convenience of taking the active ingredient in an individual, such as an animal, having difficulty in oral intake.
  • 1 is a diagram showing the results of confirming the change in cell proliferation rate in the normal control group and the inducing control in which inflammation was induced by Gingival LPS, and the experimental group treated with the test substance of the present invention by concentration through MTT analysis.
  • FIG. 2 is a diagram showing the results of confirming the PEG2 inhibitory activity through a change in the concentration of PGE2 in the normal control group, the trigger control in which inflammation was induced with Gingival LPS, and the experimental group treated with the test substance of the present invention by concentration.
  • FIG. 3 is a diagram showing a phenomenon in which a mother film and an original film are separated during a film casting process.
  • Figure 4 is a diagram showing an oral disintegrating film prepared including egg yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the present invention relates to an antibacterial composition for inhibiting oral bacteria including egg yolk powder, Eoseongcho extract and Sambaekcho extract, and a composition for preparing an oral disintegrating film comprising them.
  • the present invention relates to a use of a composition comprising egg yolk powder, Eoseongcho extract and Sambaekcho extract for use in inhibiting oral bacteria.
  • the present invention relates to a use for preparing an antibacterial composition for inhibiting oral bacteria including oral bacteria yolk powder, Eoseongcho extract, and Sambaekcho extract.
  • the antibacterial composition of the present invention can effectively inhibit the proliferation of harmful oral bacteria present in the oral cavity, and can suppress inflammation caused by oral bacteria.
  • the present invention is characterized in that it comprises egg yolk powder, Eoseongcho extract, and Sambaekcho extract as active ingredients in order to show the oral bacteria inhibitory effect.
  • the yolk powder of the present invention may be a sweetened yolk powder, and may include Egg yolk IgY (immunoglobulin Y).
  • the Eoseongcho extract or the Sambaekcho extract may be extracted and separated from Eoseongcho or Sambaekcho using a method known in the art for extraction and separation, and may be purchased from a company such as Dadang & Co., Ltd. Can be used.
  • The'extract' as defined in the present invention is extracted from Eoseongcho or Sambaekcho using an appropriate solvent, and includes, for example, a crude extract of Eoseongcho or Sambaekcho, a polar solvent-soluble extract, or a non-polar solvent-soluble extract.
  • all of the outposts, seeds, stems, leaves, and flowers of Eoseongcho or Sambaekcho can be used without limitation.
  • any solvent may be used as long as it is a pharmaceutically acceptable solvent, and water or an organic solvent may be used, but is not limited thereto, but the extract of the present invention includes water, 1 to 1 carbon atoms. It can be extracted with one type of extraction solvent selected from the group consisting of alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, formic acid, cyclohexane, and mixtures thereof. It can be extracted using water.
  • any one of methods such as hot water extraction, cold precipitation extraction, reflux cooling extraction, solvent extraction, steam distillation method, ultrasonic extraction method, elution method, compression method, etc. can be used.
  • the desired extract may be further subjected to a conventional fractionation process, or may be purified using a conventional purification method.
  • Eoseongcho or Sambaekcho extract of the present invention can be extracted, fractionated, and purified including, without limitation, methods known in the art. Therefore, in the present invention, the extract of Eoseongcho or Sambaekcho is a concept including all extracts, fractions and purified products obtained in each step of extraction, fractionation or purification, their dilutions, concentrates or dried products.
  • the active ingredients of the present invention egg yolk powder, Eoseongcho extract, and Sambaekcho extract can be included in the composition in a mass ratio of 1 to 10: 0.1 to 5: 1 in order to achieve the purpose of suppressing oral bacteria, preventing, treating, and improving oral diseases. And, preferably, it may be included in a mass ratio of 1 to 5: 0.3 to 0.8: 1, and in one embodiment of the present invention, the yolk powder: Eoseongcho extract: Sambaekcho extract is 3:0.5:1 mass ratio of 30mg, 5mg, 1mg A composition containing was used.
  • the antimicrobial composition for inhibiting oral bacteria including the yolk powder, Eoseongcho extract and Sambaekcho extract of the present invention is a variety of oral bacteria that can cause diseases in the oral cavity Streptococcus mutans , Streptococcus sanguinis ), Streptococcus sobrinus , Streptococcus ratti , Streptococcus criceti , Streptococcus anginosus Actinobacillus actinomycetemcomitans , Tannerella forsythia , Treponemadenticola and Fusobacterium nucliatum nucleatum ), Porphyromonas gingivalins ( Porphyromonas gingivalis ) or Porphyromonas canginsivalis ( Porphyromonas cangingivalis ), and is preferably a bacterium that causes periodontal diseases including periodontitis or gingivitis in the oral cavity, Porphyromonas gingival
  • the antimicrobial composition for inhibiting oral bacteria of the present invention may additionally contain a component that enhances flavor for the purpose of enhancing the preference when administered orally, and may include, for example, beef flavor, chicken flavor, pork flavor, spices, etc. have.
  • the antimicrobial composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, toothpaste, mouthwash, mouthwash, gum, candy, mouth spray, oral ointment, oral varnish, oral cavity Mouthwash, oral patch, oral disintegrating film, gum and gum massage cream, etc. may have formulations, but are not limited thereto, and preferably toothpaste, oral rinse, oral spray, oral ointment, oral patch, oral cavity It can be prepared in one type of formulation selected from the group consisting of a disintegrating film and a gum, more preferably an oral disintegrating film formulation.
  • the present invention is a pharmaceutical composition for preventing or treating oral diseases, including yolk powder, Eoseongcho extract and Sambaekcho extract, a health functional food composition for preventing or improving oral diseases, a quasi-drug composition for preventing or improving oral diseases, and preventing or improving oral diseases It relates to a veterinary composition for use.
  • oral disease refers to various diseases occurring in the oral region, and the oral region refers to a space in the mouth that is connected from the front lip to the posterior oral cavity to the pharynx.
  • the oral disease is a disease occurring in the oral cavity, it is a concept that includes all regardless of the condition, and preferably, one selected from the group consisting of plaque, bleeding gums, bad breath, aching teeth and dental caries, periodontitis and gingivitis It may be more than, more preferably periodontitis or periodontitis.
  • Gingivitis or periodontitis is a type of periodontal disease, which refers to a disease that causes inflammation in the gingiva, periodontal ligaments and bone tissues that support teeth.
  • Gingivitis is an inflammatory disease that is limited to soft tissues and gums, and is defined as periodontitis when the inflammation has progressed to around the gum bones other than the gums.
  • LPS Lipopolysaccharids
  • the yolk powder, Eoseongcho extract, and Sambaekcho extract of the present invention inhibit the proliferation of bacteria that cause periodontal disease, such as Porphyromonas gingivalins or Porphyromonas canginivalis, and can effectively inhibit the inflammatory LPS induced thereby .
  • Periodontal disease or periodontal disease, including gingivitis has the effect of preventing or treating, improving.
  • the egg yolk powder, Eoseongcho extract, and Sambaekcho extract are preferably contained in an amount of 0.01 to 95 parts by weight based on the total 100 parts by weight of the pharmaceutical composition, and more preferably 1 to 80 parts by weight. If the content is less than 0.01 parts by weight, the dosage efficiency may be deteriorated, and if it exceeds 95 parts by weight, there may be difficulties in formulation.
  • the pharmaceutical composition according to the present invention may contain a pharmaceutically effective amount of egg yolk powder, Eoseongcho extract, or Sambaekcho extract alone, or may contain one or more pharmaceutically acceptable carriers, excipients, or diluents.
  • the egg yolk powder, Eoseongcho extract, and Sambaekcho extract of the present invention may be included in a pharmaceutically effective amount, and "pharmaceutically effective amount" means, for example, porphyromonas gingivalins or porphyromonas canginivali, which are periodontal disease-causing bacteria. It refers to an amount sufficient to prevent, improve, or cure periodontal diseases that may occur by inhibiting the growth of S.
  • pharmaceutically acceptable refers to a composition that is physiologically acceptable and, when administered to an individual, does not usually cause allergic reactions such as gastrointestinal disorders, dizziness or similar reactions.
  • the pharmaceutical composition according to the present invention is preferably formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and oral disintegrating films according to a conventional method.
  • oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and oral disintegrating films according to a conventional method.
  • Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, recently Mack Publishing Company, Easton PA.
  • Carriers, excipients and diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like.
  • Solid preparations for oral administration include films, tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient in the composition, such as starch, calcium carbonate, and sucrose. , Lactose, gelatin, etc. are mixed to prepare.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included.
  • the pharmaceutical composition of the present invention is an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal, or human conceived by a researcher, veterinarian, doctor or other clinician, that is, the symptom of the disease or disorder being treated. It can be administered in a therapeutically effective amount, which is an amount that induces remission. It is apparent to those skilled in the art that the therapeutically effective dosage and frequency of administration of the pharmaceutical composition of the present invention will vary according to the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, and general health of the patient.
  • the pharmaceutical composition of the present invention may be administered in an amount of 1 to 10,000 mg/kg/day, preferably 1 to 200 mg/kg/day, and may be administered once a day or several times. It can also be administered separately.
  • the pharmaceutical composition of the present invention can be administered to a subject by various routes. Any mode of administration can be expected, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or by intracerebrovascular injection, but most preferred is oral administration.
  • the pharmaceutical composition according to the present invention may be used alone, but according to the choice of a person skilled in the art, other suitable treatment methods (e.g., surgery, radiation therapy, hormone therapy, chemotherapy and biological It can be used in combination with the method of using a reaction regulator, etc.).
  • other suitable treatment methods e.g., surgery, radiation therapy, hormone therapy, chemotherapy and biological It can be used in combination with the method of using a reaction regulator, etc.
  • prevention may mean any action of inhibiting or delaying the onset of oral diseases by administering the composition for preventing or treating oral diseases according to the present invention to an individual.
  • treatment may refer to any action in which the composition according to the present invention is administered to an individual suspected of oral disease to improve or benefit from symptoms related to oral disease.
  • the term "improvement” may mean any action that at least reduces the severity of a parameter related to the condition being treated, for example, symptoms.
  • the term "individual" may mean all animals including humans who have or are likely to develop oral disease.
  • the present invention relates to a method for preventing or treating oral diseases comprising the step of administering to an individual a composition comprising egg yolk powder, Eoseongcho extract and Sambaekcho extract.
  • the type of food is not particularly limited, and may include all foods in a conventional sense.
  • foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea , Drinks, alcoholic beverages, and vitamin complexes.
  • the composition may be added as it is or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the term "food” refers to a natural product or processed product containing one or more nutrients, and preferably refers to a state that can be eaten directly through some degree of processing, and is a common meaning,
  • the food composition is intended to include all foods, food additives, health functional foods and beverages.
  • Foods to which the composition of the present invention can be added include, for example, various foods, beverages, gum, candy, tea, vitamin complexes, and functional foods.
  • food in the present invention includes special nutritional foods (e.g., formula, infant food, etc.), processed meat products, fish meat products, tofu, muk, noodles (e.g., ramen, noodles, etc.), health supplement food, seasoning food ( Example, soy sauce, miso, red pepper paste, mixed sauce, etc.), sauces, confectionery (eg, snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruit, vegetable beverages, soy milk, fermented beverages, ice cream, etc.), natural seasonings (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages, and other health supplements.
  • the food, beverage or food additive may be prepared by a conventional
  • the term "health functional food” refers to food manufactured and processed by extracting, concentrating, refining, mixing, or extracting, concentrating, refining, and mixing specific ingredients as raw materials for the purpose of supplementing health. It refers to foods designed and processed to sufficiently exert biological control functions such as biological defense, biological rhythm control, and disease prevention and recovery by the above ingredients, and related to the prevention of diseases or recovery of health, etc. It refers to something that can perform a function.
  • composition according to the present invention when used as a health functional food, it may be added as it is or may be used with other foods or food ingredients, which may be selected and used appropriately as needed.
  • the composition according to the present invention can be used.
  • Fermented milk health functional foods that may contain the composition of the present invention include, for example, yogurt, calpis, cheese, butter, and the like, and fermented products include tofu, miso, cheonggukjang, jelly, kimchi, and the like.
  • the composition according to the present invention may mix well-known additives and other suitable auxiliary ingredients that may be contained in a health functional food according to the choice of a person skilled in the art.
  • the composition of the present invention When using the composition of the present invention as a quasi-drug, the composition may be added as it is or may be used with other quasi-drug components, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the present invention when used as a quasi-drug composition, it can be prepared and used in formulations such as toothpaste, oral cleansers, oral rinses, oral sprays, and oral disintegrating films as oral compositions.
  • the present invention relates to a composition for preparing an oral disintegrating film for preventing or improving oral diseases, including egg yolk powder, Eoseongcho extract, Sambaekcho extract, and film forming agent.
  • the Orally Disintegrating Film of the present invention can be used interchangeably with an oral film, an oral dissolving film, etc., and can be taken without water, so not only the elderly who have difficulty in taking tablets or capsules, It is very useful for children, the handicapped, patients lying in bed, and busy modern people. It can also be used for veterinary purposes in animals that are difficult to ingest drugs.
  • the antimicrobial composition contained in the oral disintegrating film has the advantage of being directly applied to the oral cavity and staying there, and an individual who has difficulty in taking the drug can take it without reluctance to suppress oral bacteria.
  • the oral disintegrating film of the present invention has physical properties suitable for the film and can be formulated for the purpose of facilitating dissolution of the included antimicrobial composition, including a film forming agent, a disintegrant, a plasticizer, an emulsifier, a sweetener, etc. Can be formulated.
  • the film-forming agent refers to a water-soluble polymer for the purpose of facilitating film formation, and fluran, gelatin, pectin, low viscosity pectin, hydroxypropylmethylcellulose, low viscosity hydroxypropylmethylcellulose, and hydride Roxyethylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, polyvinyl alcohol, polyacrylic acid, methyl methacrylate copolymer, carboxyvinyl polymer, polyethylene glycol, alginic acid, low viscosity alginic acid, sodium alginate, carrageenan, modified starch, casein, Whey protein isolate, soy protein isolate, zein, leban, elcinan, gluten, acacia gum, carrageenan, gum arabic, guar gum, locust bean gum, xanthan gum, gellan gum, and at least one selected from the group consisting of agar It may be a water-soluble polymer.
  • fluran may be used as a film forming agent, and when fluran is used, it may be included in 35 to 60% by weight, preferably 45 to 55% by weight, based on the total solid content of the composition for film production. .
  • the composition for producing an oral disintegrating film of the present invention may contain the yolk powder, Eoseongcho extract and Sambaekcho extract in a mass ratio of 1 to 10: 0.1 to 5: 1 in the composition in order to achieve an oral bacteria inhibiting effect, preferably 1 to 5: may be included in a mass ratio of 0.3 to 0.8: 1.
  • composition for producing an oral disintegrating film of the present invention may further include flavoring flavor for the purpose of improving consumer preference, and preferably may include flavoring flavor in liquid form. If the flavoring flavor exceeds 6% by weight of the total solids of the composition for film production, oil may leak during the production of the oral disintegrating film, resulting in separation of the mother film and the original film, and disintegration may not be achieved when feeding the individual. Therefore, seasoning flavor is preferably included in a liquid form in the composition for producing a film, and may be included in 2 to 5% by weight, more preferably 2 to 4% by weight of the total solid content of the composition for film production.
  • the seasoning flavor may include, without limitation, various natural and synthetic flavoring flavors that can be used as food additives, most preferably beef flavor.
  • the composition for preparing an oral disintegrating film of the present invention may contain egg yolk powder, Eoseongcho extract, Sambaekcho extract and film forming agent to achieve oral disintegration, film formulation, and oral bacterial inhibitory effect upon oral disintegration, and to enhance preference It may further include a liquid seasoning flavor.
  • the liquid seasoning flavor is included in this way, the egg yolk powder, Eoseongcho extract, Sambaekcho extract, and liquid seasoning flavor may be included in the composition for oral disintegration film production in a mass ratio of preferably 1 to 5: 0.3 to 0.8: 1: 0.3 to 0.8. have.
  • composition for preparing an oral disintegrating film of the present invention may contain one or more surfactants selected from the group consisting of nonionic surfactants, cationic surfactants, anionic surfactants, and zwitterionic surfactants, and preferably Sodium lauryl sulfate (SLS), glycerin fatty acid ester, sucrose fatty acid ester, lecithin, enzyme-treated lecithin, polysorbate, sorbitan fatty acid ester and sucrose fatty acid ester may be one or more selected from the group consisting of, and more preferably lauryl Sodium sulfate (SLS) and/or polysorbate.
  • surfactants selected from the group consisting of nonionic surfactants, cationic surfactants, anionic surfactants, and zwitterionic surfactants, and preferably Sodium lauryl sulfate (SLS), glycerin fatty acid ester, sucrose fatty acid ester, lecithin, enzyme-treated lec
  • the polysorbate is polysorbate 20 (monolauric acid), 40 (monopalmitic acid), 60 (monostearic acid), 65 (tristearic acid), 80 (monooleic acid) can be used without limitation, Most preferably, it may be polysorbate 20.
  • the oral disintegrating film of the present invention may additionally contain a sweetener, and sorbitol solution, sucralose, sodium chloride, mannitol, aspartame, acesulfame salt, saccharin salt, neotime, cyclamate salt within the limit of not impairing the physical properties of the film It may be one or more selected from the group consisting of taumatin, nahan fruit extract, licorice extract and enzyme-treated stevia.
  • test substance that suppresses inflammation in the oral cavity and inhibits the proliferation of oral bacteria.
  • the activity of inhibiting oral bacteria was confirmed below.
  • Sweetened egg yolk powder was purchased from Adbiotech and used.
  • Eoseongcho was washed with purified water, and purified water 15 times the extraction concentration was added and extracted at 60°C for 2 hours.
  • the obtained Eoseongcho water extract was filtered through a filter cloth or a 0.45 ⁇ m stainless steel mesh net.
  • Sambaekcho extract was also obtained by water extraction in the same manner as Eoseongcho extract.
  • HGF-1 Human gingival fibroblasts (HGF-1) were purchased from ATCC and used to analyze the effect on the dental cell environment (ATCC CRL-2014, 63449675). These cells are known to be the most suitable cells for oral studies, and are known to be most suitable for measuring PGE2 after Gingival LPS treatment.
  • Gingival fibroblasts were cultured from April 24, 2018 to May 2, 2018 in an incubator set at 37°C, 95% humidity, and 5% CO 2 . During the incubation period, temperature, humidity, and CO 2 The concentration was checked every 8 hours. DMEM medium, 10% FBS, 2 mL L-glutamine, 50 U/mL penicillin, and 50 ⁇ g/mL streptomycin were used for this experiment. For cell culture, a 75 cm 2 flask was used. At this time, the cells were cultured at a density of 5 X 10 6 cells/flask and replaced with fresh medium every 48 hours. After observing the degree of cell proliferation, it was isolated when proliferating more than 70%.
  • MTT assay Thiazolyl Blue Tetrazolium Blue; Sigma, M5655 was performed to confirm whether the test substance prepared in Example 1 exhibits toxicity to oral cells.
  • Gingival LPS 1 ⁇ g/mL was treated as an inflammatory substance, and the test substance prepared in Example 1 was changed to 5 to 1000 ⁇ g/mL, treated on HGF-1 cells, and cultured for 24 hours, after which the cell proliferation rate and PGE2 concentration The change of was measured.
  • Table 2 shows the test groups used for the test.
  • the concentration of PGE 2 increased rapidly by Gingival LPS treatment, and significantly decreased in a concentration-dependent manner by treatment of the test substance. Therefore, it was confirmed that the test material prepared in Example 1 can effectively inhibit PGE 2 , a product of inducing gingival inflammation in oral cells.
  • Example 1 In order to determine whether the preparation material of Example 1 exhibits an inhibitory effect on oral bacteria, the oral bacteria Porphyromonas gingivalis (P. cangingivalis ) and Porphyromonas cangingivalis ( Porphyromonas cangingivalis, P. cangingivalis ) , followed by a MIC ( minimal inhibition concentration) test.
  • P. cangingivalis And P. gingivalis were cultured for 48 hours at 37 °C anaerobic conditions using a medium prepared by adding hemin, vitamin K 3 and 5% sheep blood to Tryptic soy broth.
  • the first cultured bacteria were smeared on Tryptic soy agar + hemin + vitamin K 3 + 5% sheep blood to measure the number of bacteria, and then diluted to a concentration of 2.5 X 10 5 CFU/mL and used for MIC test.
  • Each test substance prepared in Example 1 was diluted in 96 wells by the same dilution factor, and then the same amount of bacteria was inoculated. After incubation for 48 hours, the absorbance was measured using a wavelength of 600 nm (Biotek, Epoch 2), and n number of the dilution factor of each test substance was set to 3 for accurate measurement.
  • each bacterium was stably cultured in a medium suitable for proliferation, maintained at least 2.5 X 10 5 CFU/mL, and cultured for 48 hours in an anaerobic 37° C. culture condition.
  • the test substance was treated in an equal amount in each well (96 well plate), and then the same amount of bacteria was inoculated into each well and incubated for 48 hours under anaerobic conditions at 37°C.
  • the absorbance (optical density, 600 nm) of each well was measured through a microplate reader to confirm antimicrobial activity and MIC.
  • IC80 Inhibitory concentration 80% maximal
  • IC70 Inhibitory concentration 70% maximal
  • IC50 Inhibitory concentration 50% maximal
  • the oral disintegrating film formulation was prepared using the yolk powder, Eoseongcho extract, and Sambaekcho extract, which confirmed the effect of inhibiting gingivitis and oral bacteria through Examples 2 and 3.
  • Beef flavor was added to enhance the preference, and preparation was carried out while varying the form of addition in powder or liquid form, and different amounts of 2.5, 5, and 10 mg.
  • As a result of manufacturing the oral disintegrating film according to the form and amount of beef flavor added if the beef flavor is added in powder or liquid form over 10 mg and exceeds 6% of the total solid content, a lot of oil spills out and disintegrates well during film production. It was confirmed that it was not lost.
  • a phenomenon in which the mother film and the original film are separated as shown in FIG. 3 occurred during the film casting process.
  • the composition of the film solution and the size of the film were adjusted, and with a composition that can achieve both film casting and disintegration effects, sweetened egg yolk powder (from Adbiotech) 30 mg, Sambaekcho extract 10mg, Eoseongcho extract 5mg And 5 mg of liquid beef flavor was derived, and a final oral disintegrating film was prepared by setting the size of the film to 27 * 40 mm, and the prepared oral disintegrating film is shown in FIG. 4. Component information and film size information used in the preparation of the oral disintegrating film are shown in Table 7 below.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional tablet preparation method.
  • the above ingredients are mixed and filled into gelatin capsules to prepare tablets.
  • Purified water was added and the total was adjusted to 1,00ml.
  • the above ingredients are mixed according to a conventional method for preparing a liquid, and then filled in a brown bottle and sterilized to prepare a liquid.
  • Vitamin A acetate 70 ⁇ g
  • Vitamin B6 0.5 mg
  • Vitamin B12 0.2 ⁇ g
  • composition ratio of the vitamin and mineral mixture is relatively suitable for the health functional food, but it is possible to arbitrarily modify the composition, and the above ingredients are mixed according to the general health functional food manufacturing method. Then, it can be used in the manufacture of a health functional food composition (eg, nutritional candy, etc.) according to a conventional method.
  • a health functional food composition eg, nutritional candy, etc.
  • the resulting solution is filtered and obtained in a sterilized 2 liter container, sealed and sterilized, and stored in a refrigerator. It is used to prepare the health functional beverage composition of the present invention.
  • composition ratio is composed of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the intended use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne : une composition antimicrobienne pour l'inhibition de bactéries buccales qui inhibe les bactéries provoquant une maladie buccale et l'inflammation, et peut ainsi prévenir, soulager et traiter des maladies buccales ; une composition pharmaceutique pour prévenir ou traiter des maladies buccales ; une composition alimentaire fonctionnelle pour la santé ; et une composition quasi médicamenteuse. La poudre de jaune d'œuf, un extrait de Houttuynia cordata et un extrait de Saururus chinensis de la présente invention inhibent l'inflammation induite par des infections par des bactéries provoquant une maladie parodontale, et peuvent inhiber efficacement, à de faibles concentrations, les bactéries orales classiques de Porphyromonas gingivalis ou Porphyromonas cangingivalis, et peuvent ainsi être efficacement utilisés dans la prévention ou le traitement de diverses maladies buccales.
PCT/KR2019/004204 2019-04-04 2019-04-09 Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale WO2020204242A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190039471A KR20200117411A (ko) 2019-04-04 2019-04-04 구강 세균 억제용 항균 조성물 및 구강붕해필름
KR10-2019-0039471 2019-04-04

Publications (1)

Publication Number Publication Date
WO2020204242A1 true WO2020204242A1 (fr) 2020-10-08

Family

ID=72666821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/004204 WO2020204242A1 (fr) 2019-04-04 2019-04-09 Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale

Country Status (2)

Country Link
KR (1) KR20200117411A (fr)
WO (1) WO2020204242A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102621090B1 (ko) * 2023-08-20 2024-01-23 주식회사 구강닥터 소취와 충치예방이 가능한 마시는 가글액 조성물 및 그의 제조방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152425A (ja) * 1998-01-05 1998-06-09 Lion Corp 口腔用組成物
KR20010075347A (ko) * 1998-09-25 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 신속히 용해하는 경구용 소모 필름
KR20100018325A (ko) * 2008-08-06 2010-02-17 경상대학교산학협력단 충치원인균의 치아부착 억제용 조성물
KR20120093607A (ko) * 2011-02-15 2012-08-23 (주)한일제약 구강용 액상조성물
KR20150137273A (ko) * 2014-05-29 2015-12-09 주식회사 피비에스 충치균인 뮤탄스균과 치주질환원인균인 진지발리스균에 대한 살균효과를 가지는 천연 생약성분 추출물을 함유한 치은염, 치주염 예방 조성물 및 그의 제조방법
KR101843750B1 (ko) * 2016-11-23 2018-04-05 주식회사 케이원 산삼 농축액을 포함하는 구취제거용 구강붕해필름 및 그 제조방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152425A (ja) * 1998-01-05 1998-06-09 Lion Corp 口腔用組成物
KR20010075347A (ko) * 1998-09-25 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 신속히 용해하는 경구용 소모 필름
KR20100018325A (ko) * 2008-08-06 2010-02-17 경상대학교산학협력단 충치원인균의 치아부착 억제용 조성물
KR20120093607A (ko) * 2011-02-15 2012-08-23 (주)한일제약 구강용 액상조성물
KR20150137273A (ko) * 2014-05-29 2015-12-09 주식회사 피비에스 충치균인 뮤탄스균과 치주질환원인균인 진지발리스균에 대한 살균효과를 가지는 천연 생약성분 추출물을 함유한 치은염, 치주염 예방 조성물 및 그의 제조방법
KR101843750B1 (ko) * 2016-11-23 2018-04-05 주식회사 케이원 산삼 농축액을 포함하는 구취제거용 구강붕해필름 및 그 제조방법

Also Published As

Publication number Publication date
KR20200117411A (ko) 2020-10-14

Similar Documents

Publication Publication Date Title
KR20150050239A (ko) 투센다닌을 함유하는 구강 질환의 예방 또는 치료용 조성물
WO2012070890A2 (fr) Composition pharmaceutique comportant un extrait de lonicera japonica pour prévenir et traiter le reflux gastro-oesophagien pathologique
WO2010087565A2 (fr) Nouvelle utilisation de la pipérine
WO2021149880A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la croissance capillaire, comprenant, en tant que principe actif, un extrait mixte de concombre, d'aubergine et d'escargot
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2017204547A1 (fr) Protéines polyvalentes de capture de virus et leur procédé de préparation
WO2020204242A1 (fr) Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale
WO2024090747A1 (fr) Composition comprenant du cannabidiol et de la taurine pour prévenir ou traiter la parodontite
WO2018212598A1 (fr) Composition pour la prévention ou le traitement de maladies associées à une déficience cognitive, contenant un extrait d'euonymus hamiltonianus wall.
WO2020235828A1 (fr) Composition pour l'inhibition d'ostéoclastes contenant un extrait d'agastache rugosa en tant que principe actif, et son utilisation
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2015174636A1 (fr) Composition pour la prévention et le traitement de l'infertilité masculine, contenant un extrait d'herbes mixtes en tant qu'ingrédient actif et utilisation de celle-ci
WO2019212300A1 (fr) Composition comprenant un extrait d'aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson
WO2014126285A1 (fr) Composition pour la prévention ou le traitement de la fibrose rénale, comprenant du diméthylfumarate en tant que principe actif
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l'ostéoporose et contenant un extrait de germe de soja
WO2016190481A1 (fr) Adjuvant anticancéreux contenant un composé de ginsenocide de panaxadiol
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2023038258A1 (fr) Nouvelle souche lactobacillus gasseri lm1065 issue du lait maternel, et composition pour soulager le syndrome prémenstruel comprenant ladite souche ou son produit de culture
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2020256381A1 (fr) Composition de blanchiment de la peau comprenant en tant que principe actif de l'octadécène ou un sel de celui-ci
WO2020197255A1 (fr) Composition pour le blanchiment de la peau contenant guaiacol, phytol et carvacrol comme principes actifs
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19923138

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19923138

Country of ref document: EP

Kind code of ref document: A1